66935-36-2

Usage

InChI:InChI=1/C23H33N5O8S/c1-34-10-9-28(14-21(29)30)22(31)18(5-4-8-26-23(24)25)27-37(32,33)17-7-6-15-12-19(35-2)20(36-3)13-16(15)11-17/h6-7,11-13,18,27H,4-5,8-10,14H2,1-3H3,(H,29,30)(H4,24,25,26)/t18-/m0/s1

Upstream product

• 66935-35-1 N₂-(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-(2-methoxyethyl)glycine ethyl ester 
• 74-79-3 L-arginine 
• 63093-17-4 2-(6,7-Dimethoxynaphthalenyl)sulfonyl chloride 
• 63325-57-5 N₂-(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl chloride hydrochloride 
• 63093-14-1 N₂-(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginine 

Relevant academic research and scientific papers

Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N alpha-substituted L-arginine.

A series of N alpha-(arylsulfonyl)-L-arginine amide derivatives having carboxamide N-substituents with a carboxyl group was prepared and tested as inhibitors of the clotting activity of thrombin. The most inhibitory compounds were obtained when a carboxyl group was introduced into the carbon next to the amide nitrogen of N alpha-(arylsulfonyl)-L-arginine amide derivatives, e.g., N alpha-(arylsulfonyl)-L-arginyl-N-butyl-, N-(methoxyethyl)- or N-(tetrahydrofurfuryl)glycine and 4-alkyl-1-[N alpha-(arylsulfonyl)-L-arginyl]-2-piperidinecarboxylic acid, with an I50 of 1-3 X 10(-7) M.

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

N2 -arylsulfonyl-argininamides and the pharmaceutically acceptable salts thereof

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof

N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof

N2 -alkoxynaphthalenesulfonyl-L-arginiamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis, and are prepared by reacting N2 -alkoxynaphthalenesulfonyl-L-arginyl halide with a secondary amine.